Introduction: Atorvastatin is a selective, competitive inhibitor of HMG-CoA reductase, the enzyme responsible for converting 3-hydroxy-3-methylglutaryl-co-enzyme A to mevalonic acid, a precursor of sterols, including cholesterol . Purpose: The purpose of this study was to investigate the therapeutic value of atorvastatin compared to other active substances in cardiological patients and to investigate the appropriate therapeutic dose. Material and Method: A systematic review was carried out involving 4 studies. The search for scientific articles was made in the international database PUB-MED and SCOPUS. Double blind, randomized clinical trials were sought in patients with diagnosed coronary artery disease who received atorvastatin. Control of treatment efficacy was based on the recording of new episodes and / or other cardiovascular events. Results: Administration of atorvastatin 10 mg versus 2 mg of pitavastatin is similar. Also, administration of atorvastatin at a dosage of 80 mg daily is safer and results in the recording of new episodes or other cardiovascular events as opposed to ad-ministration of atorvastatin 10 mg. Conclusions: From the scientific articles found and analyzed the administration of atorvastatin to cardiac patients has similar therapeutic value compared to other active substances. Administration of atorvastatin at a dosage of 80 mg predominates over atorvastatin at a dosage of 10 mg. To be more clear about the efficacy of atorvastatin in patients with coronary artery disease compared to other statins, they should be performed in a larger population and with a longer follow up time.